Pharma Biotech and Nutrition Businesses Continue to Drive Lonza Performance in Q1 2019
(WorldNews Switzerland)

Continued positive momentum in Pharma Biotech & Nutrition All investments in healthcare businesses progressing as planned to further accelerate growth Specialty Ingredients continued to face headwinds in Q1 2019 Measures to mitigate challenges in specialty ingredients businesses under implementation Outlook 2019 maintained and accelerated portfolio review ongoing Quote from Lonza Group CEO Marc Funk: `Q1 results demonstrate that Lonza today has two segments operating in different markets and growing at varying paces; so their performance and challenges should not be compared. `Our Pharma Biotech & Nutrition business continued to outperform. We are investing to further accelerate growth in...